Literature DB >> 32127283

A Comparison of Intranasal Dexmedetomidine and Dexmedetomidine-Ketamine Combination Sedation for Transthoracic Echocardiography in Pediatric Patients With Congenital Heart Disease: A Randomized Controlled Trial.

Mang Sun1, Hui Liu2, Qing Yu3, Yang Liu4, Jing Zhang5, Yao Lei6, Qing-Yan Zhao6, Shang-Yingying Li6, Sheng-Fen Tu7, Guang-Hui Wei1.   

Abstract

OBJECTIVES: To compare the effects of intranasal dexmedetomidine (DEX) and DEX-ketamine (KET) on hemodynamics and sedation quality in children with congenital heart disease.
DESIGN: A randomized controlled, double-blind, prospective trial.
SETTING: A tertiary care teaching hospital. PARTICIPANTS: The study comprised 60 children undergoing transthoracic echocardiography (TTE).
INTERVENTIONS: Patients were randomly allocated into the DEX group (group D [n = 30]) or the DEX-KET group (group D-K [n = 30]). Group D received 2 μg/kg of intranasal DEX; group D-K received 2 μg/kg of DEX and 1 mg/kg of KET intranasally.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was the change in hemodynamics, measured using mean arterial pressure (MAP) and heart rate (HR). Secondary outcomes were onset time, wake-up time, and discharge time. No differences were found in mean arterial pressure or heart rate. The onset time was significantly shorter in group D-K than in group D (9.6 ± 2.9 minutes v 14.3 ± 3.4 minutes; p = 0.031). The wake-up time was longer in group D-K than in group D (52 ± 14.7 minutes v 39.6 ± 12.1 minutes; p = 0.017). The discharge time was longer in group D-K than in group D (61.33 ± 11.59 minutes v 48.17 ± 8.86 minutes; p < 0.001). No differences in hemodynamics were found between the 2 groups. Intranasal DEX was found to be as effective for TTE sedation as intranasal DEX-KET, with longer onset time and shorter recovery and discharge times.
CONCLUSION: No differences in hemodynamics were found between the 2 groups. Intranasal DEX was found to be as effective for TTE sedation as is intranasal DEX-KET, with longer onset time and shorter recovery and discharge times.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  congenital heart disease; dexmedetomidine; intranasal; ketamine

Mesh:

Substances:

Year:  2020        PMID: 32127283     DOI: 10.1053/j.jvca.2019.12.045

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  3 in total

1.  A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial.

Authors:  Xinlei Lu; Ling Tang; Haiyan Lan; Chunli Li; Han Lin
Journal:  Front Pharmacol       Date:  2022-01-27       Impact factor: 5.810

2.  Comparison of nebulized dexmedetomidine and ketamine for premedication in pediatric patients undergoing hernia repair surgery: a randomized comparative trial.

Authors:  Geeta Singariya; Namita Malhotra; Manoj Kamal; Rishabh Jaju; Shruti Aggarwal; Pooja Bihani
Journal:  Anesth Pain Med (Seoul)       Date:  2022-03-30

3.  Using intranasal dexmedetomidine with buccal midazolam for magnetic resonance imaging sedation in children: A single-arm prospective interventional study.

Authors:  Bi Lian Li; Hao Luo; Jun Xiang Huang; Huan Huan Zhang; Joanna R Paquin; Vivian M Yuen; Xing Rong Song
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.